tirzepatide kidney function reduces albuminuria among adults with type 2 diabetes in SURPASS trials SURPASS-CVOT: Tirzepatide Significantly Reduces Major
Description
Lose 5-10% body weight in 56 weeks (SCALE trial).
this twincretin approach targets two incretin pathways instead of one
Water for injections
systematic review and meta-analysis
